Yosuke Shimodaira

Dr. Yosuke Shimodaira

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Science
Verified
Journal Article
Closed access
PDF file
JGJoep Grootjans
Joep Grootjans
NKNiklas Krupka
Niklas Krupka
SHShuhei Hosomi
Shuhei Hosomi
JMJuan D. Matute
Juan D. Matute
THThomas Hanley
Thomas Hanley
RBRichard S. Blumberg
Richard S. Blumberg
Stressed gut epithelium gets some relief: Immunoglobulin A (IgA) is the most abundantly expressed antibody isotype and can be found at various mucosal surfaces in the body, including the gastrointestinal (GI) tract. IgA is polyreactive and can coat and restrain both commensal bacteria and enteric pathogens. Grootjans et al. found that endoplasmic reticulum (ER) stress in the intestinal epithelial cells of mice induced the T cell– and microbiota-independent expansion of peritoneal B1b cells, which secrete IgA. Similarly, human subjects homozygous for a variant of an autophagy gene ( ATG16L1 ) known to cause ER stress showed increased numbers of GI IgA + cells compared with controls. Thus, epithelial ER stress serves as an advantageous “eustress” response that can functionally antagonize its well-characterized role in promoting inflammation. Science , this issue p. 993

1 January 2022 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TYTatsuki Yoshida
Tatsuki Yoshida
YSYosuke Shimodaira
Yosuke Shimodaira
SFSho Fukuda
Sho Fukuda
NWNoboru Watanabe
Noboru Watanabe
SKShigeto Koizumi
Shigeto Koizumi
KIKatsunori Iijima
Katsunori Iijima
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

26 August 2021 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
SFSho Fukuda
Sho Fukuda
KWKenta Watanabe
Kenta Watanabe
TYTatsuki Yoshida
Tatsuki Yoshida
STSo Takahashi
So Takahashi
SFShusei Fujimori
Shusei Fujimori
KIKatsunori Iijima
Katsunori Iijima

4 December 2020 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
KNKazuaki Norita
Kazuaki Norita
TKTomoyuki Koike
Tomoyuki Koike
MSMasahiro Saito
Masahiro Saito
HSHirohiko Shinkai
Hirohiko Shinkai
RAReiko Ami
Reiko Ami
KIKatsunori Iijima
Katsunori Iijima

7 May 2026 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
KWKenta Watanabe
Kenta Watanabe
SFSho Fukuda
Sho Fukuda
DKDai Kubota
Dai Kubota
NYNobutake Yamamichi
Nobutake Yamamichi
YTYu Takahashi
Yu Takahashi
KIKatsunori Iijima
Katsunori Iijima
Background and Aim: In Japan, gastric cancer (GC) and esophageal squamous cell carcinoma (ESCC) account for nearly all fatal upper gastrointestinal malignancies. A unified model that simultaneously predicts the incidence of these two cancers could help optimize endoscopic screening and postindex surveillance strategies. Methods: We conducted a retrospective multicenter cohort study of 33 422 individuals who underwent screening esophagogastroduodenoscopy (EGD) at 17 health check‐up institutions across Japan. Clinical and endoscopic data from the index EGD were used to develop a 5‐year risk prediction model for GC or ESCC. Significant predictors were identified using Cox regression, and a scoring system (J‐GESS score) was constructed by scaling β coefficients. Model performance was evaluated using the 5‐year inverse probability of censoring weighted (IPCW) Brier score, calibration, and c indices. Internal validation used bootstrap resampling (500 iterations) to obtain optimism‐corrected estimates. Decision curve analysis (DCA) assessed clinical utility at 5 years. Results: At 5 years, the IPCW‐estimated cumulative incidence of GC or ESCC was 0.84% (234 events). Independent predictors included older age, male sex, ever smoking, and endoscopic gastric mucosal atrophy. The model showed good calibration at 5 years (calibration‐in‐the‐large 0.005; slope 1.055; identical after optimism correction) and robust discrimination (Harrell's c index 0.81; Uno's 5‐year c index 0.81). DCA demonstrated positive net benefit across clinically relevant thresholds. Conclusion: Using routinely collected health check‐up data, we developed a unified, practical, and internally validated 5‐year prediction model for GC and ESCC. The J‐GESS score enables effective risk stratification and may inform postindex endoscopic surveillance and screening interval optimization in Japan.

8 May 2021 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YSYosuke Shimodaira
Yosuke Shimodaira
STSo Takahashi
So Takahashi
KIKatsunori Iijima
Katsunori Iijima
Background: Various molecular-targeted therapeutic agents that inhibit cytokines and immune checkpoints are used in clinical practice. Some of these biologics that control immunity, such as anti-interleukin-17, anti-programmed cell death protein-1, and anti-cytotoxic T-lymphocyte-associated protein antibodies, affect intestinal immune homeostasis and cause intestinal inflammation. Development of enteritis due to dupilumab (an anti-IL-4Ralpha monoclonal antibody) therapy is not yet reported in the literature. Case presentation: A 17-year-old man was administered an injection of dupilumab and continued to receive it for refractory atopic dermatitis. After 3 months of initiating dupilumab therapy, he developed intermittent abdominal pain, tenesmus, and had diarrhea. Colonoscopy examination showed decreased vascularity, mild friability, and erythema in the cecum, part of the ascending colon, sigmoid colon, and rectum without any pathogenic bacteria. Histological examination revealed moderate mixed inflammatory cell infiltration, cryptitis, destruction of the crypt, decreased goblet cells, mucosal erosions, and edema. He was diagnosed with UC and was prescribed oral mesalazine (4800 mg/day) treatment. Within a month of the treatment, his diarrhea improved and the frequency of defecation decreased. Conclusions: This is a first report that dupilumab mimicked ulcerative colitis. Careful monitoring for adverse effects with the onset of an intestinal inflammation will be recommended after dupilumab administration.